| WARF: P03426US |  |
| Treatment of Inflammatory Bowel Disease with 2-methylene-19-nor Vitamin D Compounds |
| INVENTORS | • | Hector DeLuca, Margherita Cantorna |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of preventing or treating inflammatory bowel diseases with vitamin D compounds.
OVERVIEW
Inflammatory bowel diseases (IBD) are characterized by chronic intestinal inflammation of obscure origin and refer to two distinct disorders: Crohn’s disease and ulcerative colitis (UC). Current methods of treating IBD, which has no known cure, have many adverse side effects.
THE INVENTION
UW-Madison researchers have developed a method of preventing or treating inflammatory bowel diseases with vitamin D compounds. The compounds used to relieve IBD symptoms belong to a class of vitamin D analogs known as the 2-methylene-19-nor-vitamin D compounds. Preferred compounds are 1alpha-hydroxy-2-methylene-19-nor-homopregnacaliferol (2-MP) and 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 (2-MD). 2-MP is non-calcemic and 2-MD can be administered at such a low dose that it doesn’t cause hyper-calcemia (elevated serum calcium).
APPLICATIONS
- Reducing or alleviating symptoms of IBD
- Preventing the onset of IBD symptoms
KEY BENEFITS
- Causes minimal adverse side effects
- Does not cause hypercalcemia
- May maintain bone density in patients receiving steroids for treatment of IBD
- May be administered in many ways, including parenterally, transdermally, orally or topically
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Inflammation
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
